GlassScriptPhysician profile
Atul Sharma
NPI 1104829241
$76,710.12
in general payments reported to CMS, 2019-2025
30 companies · $4,998 in 2025
The $4,998 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,811 · 2021: $21K · 2022: $14K · 2023: $4,277 · 2024: $10K · 2025: $4,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $6,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,680.25 |
| Food and Beverage | $6,736.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $28,867.78 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $20,479.63 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $6,315.02 | 2019-2021 | |
| Amgen INC. | $5,600.00 | 2023-2024 | Pavblu |
| Alcon Vision LLC | $4,764.97 | 2019-2025 | Constellation, Ngenuity |
| Alimera Sciences, INC. | $2,795.25 | 2020-2024 | Yutiq, Iluvien |
| Genentech USA, INC. | $2,737.62 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Notal Vision, INC. | $1,001.63 | 2022 | |
| Apellis Pharmaceuticals, INC. | $852.18 | 2023-2025 | Syfovre |
| Abbvie INC. | $626.77 | 2022-2025 | Ozurdex |
| Ani Pharmaceuticals, INC. | $488.87 | 2023-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb Americas INC. | $349.45 | 2022-2024 | Xipere, Visudyne |
| Novartis Pharmaceuticals Corporation | $302.44 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $266.33 | 2022-2023 | Eylea |
| Astellas Pharma US INC | $241.32 | 2023-2025 | Izervay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $193.62 | 2022-2024 | |
| Carl Zeiss Meditec USA, INC. | $133.33 | 2021 | |
| New World Medical,INC. | $133.09 | 2019 | |
| Dutch Ophthalmic, USA | $126.78 | 2019 | |
| Sandoz INC. | $98.43 | 2024 | Cimerli |
| Glaukos Corporation | $94.43 | 2024 | Radius |
| Novartis Pharma Ag | $92.23 | 2020 | |
| Mallinckrodt Hospital Products INC. | $23.18 | 2020 | |
| Biogen, INC. | $22.37 | 2023 | |
| Topcon Healthcare, INC. | $20.10 | 2025 | |
| Eyepoint US, INC. | $19.85 | 2022 | |
| Kala Pharmaceuticals, INC. | $18.57 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $17.44 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.45 | 2019 | |
| Merck Sharp & Dohme LLC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$441,366.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.